Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies. Our valuation framework helps you find stocks with the right balance of growth and value characteristics.
4D Molecular Therapeutics Inc. (FDMT), a clinical-stage gene therapy developer, is trading at a current price of $10.28 as of 2026-04-20, marking a 2.00% decline in recent trading. This analysis outlines key market context, technical levels, and potential near-term scenarios for the biotech stock, with no recent earnings data available for FDMT as of publication. The primary focus is on the stock’s current trading range, support and resistance markers, and the broader sector trends that may infl
4D (FDMT) Stock Beneficial Ownership (Grinds Lower) 2026-04-20 - Target Price
FDMT - Stock Analysis
3220 Comments
741 Likes
1
Cinnamon
Senior Contributor
2 hours ago
That’s some “wow” energy. ⚡
👍 110
Reply
2
Jiar
Returning User
5 hours ago
Ah, such bad timing.
👍 77
Reply
3
Lithzy
Regular Reader
1 day ago
Nothing but admiration for this effort.
👍 252
Reply
4
Brezlyn
Influential Reader
1 day ago
Comprehensive US stock regulatory environment analysis and policy impact assessment to understand business risks. We monitor regulatory developments that could create opportunities or threats for different industries and companies.
👍 137
Reply
5
Preonda
Active Contributor
2 days ago
That deserves a slow-motion replay. 🎬
👍 87
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.